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INTRODUCTION
Osteoporosis is a skeletal disorder characterized by low
bone mass and disturbances of the microarchitecture of the
bone tissue. This pathologic process results in enhanced
bone fragility and consequent increase in fracture risk [1].
Osteoporosis or low bone mineral mass occurs in more than
50% of patients after hematopoietic cell transplantation
(HCT) [2,3]. Bone loss and fracture manifest as pain and
loss of function, and they have a negative impact on quality
of life.
The pathogenesis of transplantation bone disease is
multifactorial and incompletely understood. Uncoupling of
bone formation and bone resorption is the primary cause of
o s t e o p o rosis, resulting in overactive osteoclastic bone
resorption or underactive bone osteoblastic formation. The
most common cause of osteoporosis is attributed to estrogen
and testosterone deficiency associated with menopause and
aging. Factors that predispose patients to osteoporo s i s
include a diet low in calcium, low vitamin D levels fro m
insufficient sunlight, genetic factors, and endocrine or renal
i n s u ff i c i e n c y. Hematopoietic cell transplantation and post-
transplant therapies can affect bone homeostasis by several
mechanisms: inducing pre m a t u re menopause and/or hypo-
gonadism, directly poisoning bone cells, and elevating
parathyroid hormone (PTH) levels by affecting the absorp-
tion and handling of calcium and magnesium. This re v i e w
will discuss mechanisms that regulate normal bone remodel-
ing and the transplantation-related factors that cause bone
mineral loss and osteoporosis. The effect on bone metabo-
lism of these therapies will also be discussed, as will mecha-
nisms of action of anti-osteoporosis therapies.
NORMAL BONE REMODELING
The skeleton serves 2 principal functions: it is a stru c-
tural support for mechanical needs and a storage re s e rv o i r
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ABSTRACT
Osteopenia and osteoporosis are common complications of bone marrow and peripheral blood stem cell transplan-
tation. Bone loss occurs in 50% to 60% of patients treated with the most common pre p a r a t o ry regimens. The major
causes of transplant-related bone loss are primary hypogonadism (low estrogen and testosterone), secondary hyper-
p a r a t h y roidism due to low serum calcium, and posttransplant steroid therapy. Other transplant-related tre a t m e n t s
that induce bone loss are discussed. Trabecular bone is particularly vulnerable to transplant-related therapies. The
spine and hip contain 50% to 75% trabecular bone and are most at risk for fracture after hematopoietic cell trans-
plantation (HCT). The stru c t u re of bone and the bone cells that are involved in maintaining skeletal integrity are
discussed, followed by a discussion of the transplant-related therapies that have been shown to cause damage to
bone and lead to bone loss. Recommendations for patients undergoing HCT include (1) evaluation of bone mineral
density either shortly before or shortly after transplantation and appropriate intervention and monitoring based on
the results; and (2) evaluation of estrogen and testosterone levels after HCT and replacement when appro p r i a t e ;
and (3) administration of bisphosphonate therapy to all patients on steroids for >2 months. Early intervention and
p revention of bone loss can have a tremendous clinical impact for patients undergoing HCT because once signifi-
cant bone loss has occurred, it is difficult to re v e r s e .
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of calcium and phosphate for metabolic demands. Cort i c a l
bone forms the solid outer wall of all bones and accounts
for 80% of bone mass [4]. Trabecular or cancelous bone,
the honeycomb-like stru c t u re in contact with the bone
m a rro w, re p resents 20% of the bone mass. The skeleton
is constantly remodeled and regenerated by a dynamic
p rocess of resorption and replacement. The 2 principal
cell types responsible for bone remodeling are the osteo-
clast, which resorbs bone, and the osteoblast, which form s
bone. Osteoclasts and osteoblasts are organized in gro u p s
called basic multicellular units (BMU) [5] (Figure 1). The
average life span of a BMU is 6 months, and it is esti-
mated that there is complete renewal of the entire skele-
ton every 10 years [5].
CELLULAR COMPONENTS OF BONE
Osteoclastic activation is the initial step in the re m o d e l i n g
sequence. The osteoclast, a multinucleated hematopoietic cell
derived from the monocyte/macrophage lineage, forms a ru f-
fled membrane border and secretes a variety of specialized
factors, including proteases, collagenases, phosphatases, and
p rotons that break down the bone matrix, releasing mineral
ions into the extracellular fluid. Osteoclastic diff e re n t i a t i o n
and activation are regulated principally by osteoblasts. The
osteoblast is a mesenchymally derived stromal cell that is
involved in the formation of the organic bone matrix and the
mineralization of new bone. The periosteum and bone mar-
row are important sources of mesenchymal osteopro g e n i t o r
cells that give rise to osteoblasts, chondrocytes, adipocytes,
Figure 1. Bone cell function. The bone remodeling unit consists of an osteoblast and an osteoclast. Osteoblasts (OB) produce bone matrix proteins and regulate the
incorporation of calcium and phosphate in this organic matrix. OB also regulate osteoclasts (OC) through the secretion of macrophage colony-stimulating factor,
RANK ligand, and other cytokines. Osteoclasts produce proteases and H+ protons that degrade the calcified bone matrix. Parathyroid hormone–activated vitamin D
(1,25[OH]2VitD3) and estrogen regulate bone remodeling chiefly through their actions on osteoblasts [9].
F i g u r e 2. Osteoblast lineage. The osteoblast is derived from a pluripotent mesenchymal stem cell. Osteoblasts secrete the organic bone matrix proteins. As
osteoblasts mature, they secrete proteins important for the calcification of the bone matrix and develop into the terminally differentiated osteocyte. The osteocyte is
embedded within the calcified bone matrix and communicates with other osteocytes and periosteal osteoblasts via cellular extensions [6].
167B B & M T
and myoblasts [6,7], as seen in Figure 2. The cuboidal-shaped
osteoblasts synthesize the bone matrix, consisting of collagen
type I, alkaline phosphatase, transforming growth factor β
( T G F -β), and insulin-like growth factor 1 (IGF-1). After
bone formation is completed, the osteoblasts become flat, and
these quiescent osteoblasts are termed “lining cells” (Figure 2 ) .
Some of these osteoblasts will become buried in the mineral-
ized bone and become osteocytes, with an extensive network
of cell projections connecting them to other osteocytes and
osteoblasts. As they mature into osteocytes, osteoblasts syn-
thesize bone mineralization factors, including osteopontin,
bone sialoprotein, and osteocalcin (Table 1) [6].
GROWTH FACTORS, CYTOKINES, AND HORMONES THAT
INFLUENCE BONE DEVELOPMENT
The development and function of osteoclasts and
osteoblasts are regulated by a variety of hormones, growth
factors, and cytokines (Tables 2 and 3) that are susceptible to
d y s regulation following hematopoietic cell transplantation.
The principal growth factors involved in bone re m o d e l i n g
are IGF-1, TGF-β, and bone morphogenic proteins (BMPs)
(Table 2). IGF-1 and TGF-β are present in high concentra-
tions within the bone matrix and stimulate osteoblastic
replication and enhanced bone collagen and matrix synthesis
by osteoblasts [8,6]. TGF-β inhibits osteoclast function and
p romotes osteoclast apoptosis, resulting in an overall
decrease in bone resorption [5,9]. Therefore, the release of
T G F -β s t o red in the bone matrix during bone re s o r p t i o n
acts to inhibit further resorption and to induce bone forma-
tion. Tr a n s p l a n t - related therapies interf e re with these pro-
tective re g u l a t o ry mechanisms by stimulating excess bone
resorption through the induction of an excess of osteoclastic
activating factors, discussed below [10].
Cytokines are important for growth and diff e rentiation of
osteoclasts (Table 3). The cytokines that stimulate osteoclasts
a re made primarily by osteoblasts in response to PTH and
p a r a t h y roid hormone–activated vitamin D [1,25(OH)2Vi t D 3 ]
( F i g u re 1, Table 1). Transplantation-induced hypogonadism
and immunosuppressive therapy can trigger the production of
these osteoblast-derived cytokines, resulting in inappro p r i a t e
osteoclast activation. The most important cytokines re g u l a t i n g
osteoclast diff e rentiation and function are the newly identifie d
RANK ligand (also called TRANCE, OPGL) [11,12] and
m a c rophage colony-stimulating factor (M-CSF) [13-15].
RANK ligand, a tumor necrosis factor (TNF) receptor family
m e m b e r, is an osteoclast-activating factor that is critical to
osteoclast development and function. Osteoblast-derived
RANK ligand binds the RANK receptor on immature and
m a t u re osteoclasts, causing their diff e rentiation and activation
[12,16,17]. Osteoprotegerin (OPG) is expressed by a variety of
tissues, including lung, bone, kidney, and liver, and it inhibits
osteoclastic activation by binding RANKL and pre v e n t i n g
RANKL binding to RANK [18]. OPG has been shown to
p revent osteoporosis and increase bone mineral density when
a d m i n i s t e red to rodents [18,19]. The mechanism thro u g h
which RANK signaling affects osteoclasts is incompletely
understood; however, RANKL/OPG/RANK regulation of
osteoclasts is under intense investigation and will likely play an
i m p o rtant role in study of transplantation-related bone loss.
M-CSF has been shown to be critical to osteoclast and macro-
phage survival during maturation [20,21]. Other cytokines
i m p o rtant for growth of osteoclasts are listed in Table 3. Inter-
leukin (IL)-6 has been implicated in bone loss associated with
e s t rogen withdrawal in the mouse, as well as the osteoclastic
activation observed in myeloma patients [9,22].
PTH and 1,25(OH)2VitD3 are the principal re g u l a t o r s
of calcium homeostatis for most terrestrial vert e b r a t e s ,
including humans [23,24] (Figure 3). PTH increases circ u l a t-
ing calcium levels by several mechanisms. It stimulates the
d i ff e rentiation of committed osteoclast progenitors to fuse
and form mature multinucleated osteoclasts, and it also acti-
vates pre f o rmed mature osteoclasts to resorb bone, there b y
releasing calcium into the serum [23]. The activation of
osteoclasts by PTH occurs indirectly via stimulation of
osteoblasts. PTH binds receptors on osteoblasts, resulting in
the production of the following critical osteoclast maturation
Table 1. Osteoblast-Secreted Proteins
Bone Matrix Proteins Growth Factors
Collagen Type I RANK ligand




Matrix Gla Protein Tumor necrosis factor- α
Thrombospondin Transforming growth factor- β







Osteoblasts secrete a variety of proteins critical to the formation of the bone
matrix. Osteoblasts also regulate osteoclast formation and activation through
the production of cytokines and growth factors [9,6].
Table 2. Osteoblast Lineage Regulation
Growth factors
Insulin-like growth factor 1 Stimulatory
Transforming growth factor- β Stimulatory
Bone morphogenic protein 2, 4, and 7 Stimulatory
Basic fibroblast growth factor Stimulatory
Platelet-derived growth factor Stimulatory
Systemic hormones
Parathyroid hormone Stimulatory
Parathyroid hormone–related protein Stimulatory
1,25(OH) 2VitD3 Stimulatory
Bone formation and remodeling are regulated by growth factors and systemic
hormones. Bone morphogenic protein, insulin-like growth factor 1, and trans-
forming growth factor-β are the principal growth factors that regulate
osteoblast formation, differentiation, and matrix formation. Parathyroid hor-
mone and 1,25(OH) 2VitD3 induce osteoblasts to secrete cytokines and growth
factors that will induce osteoclast proliferation and activation [6].
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and activation factors: RANKL, M-CSF, IL-6, IL-1, and
TNF (Table 1) [23]. Transplant therapy–related toxicity of
the kidney and gut could result in calcium losses, which
would induce PTH secretion and osteoclast bone re s o r p t i o n
and bone loss. Glucocorticoids decrease serum calcium levels
and induce the secretion of PTH, resulting in increased bone
resorption (by mechanisms discussed below) [25].
Vitamin D is biologically inert and must undergo 2 suc-
cessive hydroxylation reactions in the liver and the kidney to
become the biologically active 1,25-dihydroxyvitamin D
[ 1 , 2 5 ( O H )2VitD3]. 1,25(OH)2VitD3 increases bioavailable
calcium by increasing the intestinal absorption of calcium
and phosphate. Like PTH, 1,25(OH)2VitD3 acts indire c t l y
to stimulate resorption by stimulating osteoblasts to pro d u c e
RANKL and M-CSF, as described above. 1,25(OH)2Vi t D 3
also regulates important osteoblastic bone matrix genes like
osteocalcin, osteopontin, and alkaline phosphatase by bind-
ing the specific vitamin D DNA-responsive elements pre s e n t
within the promoter regions of these genes [24]. Vitamin D
is made in the skin by the action of sunlight. Tr a n s p l a n t
patients spend prolonged periods out of the sun and often
consume a vitamin D–deficient diet. Vitamin D is rare in
foods: the major nutritional sources are fatty fish and fort i-
fied dairy products [24]. In addition, problems with liver and
kidney dysfunction in these patients can further block form a-
tion and activation of 1,25(OH)2Vi t D 3 .
MECHANISM OF TRANSPLANTATION-RELATED
OSTEOPOROSIS
Transplantation-associated osteoporosis is a side eff e c t
of heart transplantation [26], liver transplantation [27], lung
transplantation [28], and bone marrow transplantation
[2,3,29]. Immunosuppressive therapy, including cyclo-
sporine (CSP), FK506, and glucocorticoids, is one of the
principal factors leading to bone loss and osteoporosis [10].
Hypogonadism, kidney dysfunction, and malabsorption of
calcium also contribute to bone loss (Figures 3 and 4). Total
body irradiation and cranial irradiation can decrease growth
hormone (GH) levels, which leads to a decrease in the IGF-
1/insulin-like growth factor binding protein (IGFBP)-3
ratio. The GH/IGF-1 system induces the proliferation of
the epiphyseal growth plate until sex horm o n e – m e d i a t e d
epiphyseal closure occurs [30-32]. Thus, total body irradia-
tion (TBI) and cranial irradiation have important negative
e ffects on skeletal growth in children and adolescents.
Hematopoietic cell transplantation can induce bone loss and
osteoporosis because of direct toxic effects of radiation ther-
apy, chemotherapy, and cytokine therapy on bone cells and
gonadal and pituitary hormone secretion [10].
HYPOGONADISM
E s t rogen plays a vital role in maintaining bone mass.
During menopause, women undergo significant bone loss
[33]. Also, testosterone plays an important role in the mainte-
nance of the male skeleton; however, it appears that testos-
t e ro n e ’s skeletal effects may in part be mediated by aro m a t i z a-
tion of testosterone to estradiol [34]. Ovarian insuffic i e n c y
develops in 63% to 96% of premenopausal women who
receive adjuvant chemotherapy for breast cancer [35].
Women older than 40 years are particularly at risk of chemo-
therapy-induced menopause [35]. Ovarian insuff i c i e n c y
occurs in up to 92% to 100% of women after TBI and high-
dose chemotherapy. With chemotherapy as the sole condi-
tioning regimen, ovarian failure occurs in up to 70% of
patients [3]. Impaired spermatogenesis occurs in up to 75% of
HCT patients; however, testosterone levels are often norm a l
[36,37]. TBI also decreases growth hormone secretion, which
can lead to decreased IGF-1 production and possibly hypogo-
nadism [2,30]. Testicular and adrenal androgen levels are
i m p o rtant in maintenance of bone mass in men [38], but
e s t rogen also plays an important role in male bone mass, par-
ticularly in the growing skeleton [38,39]. Thus, both loss of
e s t rogen in women or decreased levels of androgens in men
can occur posttransplantation and can contribute to bone loss.
Estrogen receptors are expressed in both osteoblasts and
osteoclasts [40]. Estrogen suppresses osteoclast form a t i o n
and activity; estrogen deficiency leads to overactivity of
osteoclasts compared with new bone formation [33]. Osteo-
cyte apoptosis is increased in estrogen-deficient women
[41]. Estrogen increases osteoblast transcription of IGF-1
and TGF-β and represses osteoblast transcription of osteo-
clast-activating factors (Figure 4). There f o re, estro g e n
i n c reases bone formation and suppresses bone re s o r p t i o n
[40]. Estrogen deficiency induces osteoblast production of
osteoclast-activating factors (RANKL, IL-6) and suppresses
bone formation [9]. Induction of osteoblast secretion of
I L-6 in patients in an estrogen-deficient state is likely an
i m p o rtant mechanism of bone loss in hypogonadism [22].
Although mechanisms whereby sex steroid deficiency medi-
ates bone loss are incompletely understood [42], it is critical
to monitor gonadal function after HCT and to replace hor-
mones when appropriate to prevent hypogonadal bone loss.




Transforming growth factor- β Inhibitory
Epidermal growth factor Stimulatory
Platelet-derived growth factor Stimulatory




Macrophage colony-stimulating factor Stimulatory
Interleukin-6 Stimulatory
Interleukin-1 Stimulatory
Tumor necrosis factor Stimulatory
Interferon- γ Inhibitory
Osteoclast maturation, proliferation, and activation are regulated primarily
by cytokines secreted from osteoblasts. RANK ligand and macrophage colony-
stimulating factor are the 2 primary regulatory factors involved in matura-
tion and are necessary for mature cell function [12]. Transforming growth
factor-β is secreted by osteoblasts, stored in high levels in the bone matrix, and
is released during bone resorption and inhibits further osteoclast proliferation
[9]. Calcitonin is secreted from the medullary cells of the medulla and inhibits
osteoclast activation [9].
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GLUCOCORTICOID-MEDIATED BONE LOSS
Of patients taking steroids at doses greater than 7.5 mg
per day for longer than 6 months, 30% to 50% will have an
o s t e o p o ro s i s - related fracture [25]. Glucocorticoids have a
g reater effect on trabecular bone than on cortical bone; there-
f o re, bone loss is most rapid and fractures are most likely in
v e rtebrae, ribs, and the ends of long bones. Hematopoietic
cell transplantation patients may have had prior glucocort i-
coid therapy as part of pretransplant chemotherapy, but it is
unlikely that these short courses of glucocorticoids contribute
to clinically significant bone loss [43]. Young people who have
a high rate of bone turnover are very susceptible to glucocor-
ticoid-mediated bone loss. Deceleration of growth and
reduced total body calcium have been re p o rted in childre n
t reated with oral and inhaled glucocorticoids [25].
The 2 key pathogenic mechanisms of glucocort i c o i d -
induced osteoporosis are promotion of apoptosis of o s t e o b l a s t s
and osteocytes and inhibition of osteoblastogenesis [41]. Bone
biopsies from patients who have received chronic stero i d s
show a marked increase in osteoblast and osteocyte apoptosis
[41]. Furt h e rm o re, the accumulation of apoptotic osteocytes
may contribute to osteonecrosis. Abundant apoptotic osteo-
cytes were found in femoral heads from patients with gluco-
c o rticoid-induced avascular necrosis, but not in patients with
sickle cell disease or alcohol disease [41]. Glucocorticoids also
d e c rease the expression of TGF-β type 1 receptor and antag-
onize the effects of BMP2 and IGF-1 [41]. Glucocort i c o i d s
induce expression of peroxisome proliferator activated re c e p-
tor (PPA R ) -γ2, which could account for increased adipogene-
sis in the bone marrow while osteoblast diff e rentiation is sup-
p ressed [41]. Finally, the glucocorticoid receptor re g u l a t e s
many important osteoblast bone matrix p roteins (such as col-
lagen I, osteopontin, and alkaline phosphatase) [25] (Figure
4, Table 1). Thus, supraphysiologic glucocorticoids decre a s e
bone formation by (1) inducing osteocyte and osteoblast apo-
ptosis, (2) inhibiting osteoblast bone matrix synthesis, and (3)
d e c reasing proliferation and diff e rentiation of periosteal pre-
cursor cells [41].
G l u c o c o rticoid therapy is a potent activator of osteo-
clasts. Glucocorticoids inhibit calcium absorption from the
gut and increase calcium excretion in the kidney, resulting in
low serum calcium levels. Low serum calcium is a stro n g
stimulus for PTH production. Thus, glucocort i c o i d s
i n c rease bone resorption indirectly by increasing PTH
s e c retion [9,25]. Although glucocorticoids suppress follicle-
stimulating hormone, lutenizing hormone, and pro s t a-
glandin E2, these effects do not appear to be clinically re l evant
[41,44]. Import a n t l y, glucocorticoid-induced osteoporo s i s
and bone loss can be prevented or decreased if recognized
early and treated with bisphosphonates [41].
CYCLOSPORINE FOR GRAFT-VERSUS-HOST DISEASE
T h e re is experimental evidence that CSP and FK506
contribute to bone loss associated with transplantation [10].
H o w e v e r, CSP is usually prescribed with glucocort i c o i d s ;
c o n s e q u e n t l y, it has been difficult to define its contribution
to bone pathophysiology in humans. The exact mechanisms
of CSP’s effects on osteoblasts and osteoclasts are still
u n c l e a r. Rats given CSP and FK506 (without glucocort i-
coids) have developed severe trabecular bone loss [45].
Bone turnover is accelerated, with evidence of incre a s e d
resorption and formation. In the rat, the effect of cyclo-
sporin A (CsA) on bone is independent of decreased kidney
function [45]. Bone loss is largely prevented by anti-re s o r p-
tive agents (like the bisphosphonates) in this model. In
addition, CsA d e c reases osteoblast proliferation in vitro and
d e c reases body stores of magnesium [10]. Mg is re q u i red for
Figure 3. Regulation of serum calcium levels. C cells in the parathyroid glands sense low serum calcium levels and secrete parathyroid hormone (PTH). PTH acts
in bone to activate osteoclastic bone resorption. PTH also acts on the kidney to increase the production of active vitamin D (1,25[OH]2VitD3) and to increase renal
reabsorption of calcium renal tubule. 1,25(OH)2 acts in the bone to activate osteoclastic bone resorption. 1,25(OH)2VitD3 acts on the intestine to increase reabsorp-
tion of calcium in the gut. 1,25(OH)2VitD3 and high serum calcium levels also downregulate PTH production in the parathyroid gland.
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v i t a m i n D hydroxylation and 1,25(OH)2VitD3 pro d u c t i o n ;
thus CsA can decrease 1,25(OH)2VitD3 levels [10].
RADIATION THERAPY AND CHEMOTHERAPY
Radiation therapy to bone has been associated with
o s t e o p o rosis, increased bone fragility, radiation necro s i s ,
radiation osteitis, increased fracture rate [46-48], and radia-
tion-induced sarcoma of bone [49]. Total body irradiation is
associated with hypogonadism, which could result in osteo-
p o rosis by the mechanisms outlined above. Irradiation can
d i rectly damage bone cells and has been shown to enlarg e
resorption lacunae and to increase osteoclast number and
activity without an increase in bone formation, leading to
increased bone resorption and bone porosity [50,51]. Bone
irradiation is also associated with a decrease in viable osteo-
cytes [52]. Radiation-induced effects on osteoclast and
osteocyte populations improve with time [53].
C h i l d ren treated for acute lymphoblastic leukemia
(ALL) are particularly at risk of osteoporosis and re d u c e d
bone density [54]. Gilsanz et al. demonstrated that most of
the reductions in bone mineral density occurred in the ALL
patients who received cranial and spinal irradiation, and that
chemotherapy for the disease plays only a minor role in
bone loss after ALL [55]. On the other hand, Warner et al.
found a correlation between prior methotrexate, ifosfamide,
and bleomycin and reduction of spine bone mineral density,
and between an exposure to 6-mercaptopurine and cisplatin
and reduction of hip bone mineral density [54].
Patients undergoing standard-dose chemotherapy for
cancer treatment can be at risk for tre a t m e n t - related bone
loss and osteoporosis. Analysis of the data indicates that the
bone loss is not likely caused by the chemotherapeutic agents
themselves but by a decrease in gonadal function induced by
the chemotherapy [43,56]. Hypogonadism is a known cause
of bone loss and osteoporosis, as described above. There are ,
h o w e v e r, some chemotherapeutic agents (methotrexate, ifos-
famide, and cisplatin) that have a particular toxic effect on
bone cell function, the mechanisms of which will be briefly
described. Mechanisms of methotrexate (MTX) effects on
bone have been studied because of the observation of bone
loss in patients receiving MTX for rheumatoid art h r i t i s .
MTX induces osteopenia, probably because of a dire c t
i n h i b i t o ry effect on osteoblast proliferation and activity,
resulting in a subsequent decrease in bone formation. MTX
also stimulates osteoclast re c ruitment [40]. Patients underg o-
ing high-dose ifosfamide treatment are at high risk of devel-
oping tubular nephrotoxicity and hypophosphatemia. Long-
lasting hypophosphatemia may be associated with decre a s e d
osteoblastic activity and bone diseases, including rickets [57].
Cisplatin induces hypomagnesemia (resulting in decre a s e d
1 , 2 5 [ O H ]2VitD3 levels) and hypocalcemia (resulting in
i n c reased PTH levels). The net effect of cisplatin would be
to induce bone resorption and exacerbate bone loss [58].
OTHER THERAPIES THAT INDUCE BONE LOSS
H e p a r i n
One third of patients on long-term heparin therapy
have reductions in bone density [59]. Heparin leads to tra-
becular bone loss, not only by increasing osteoclastic bone
resorption but also by decreasing osteoblastic bone form a-
tion [59]. The biologic mechanisms through which heparin
affects osteoblasts and osteoclasts are unknown. Low molec-
ular weight heparin (LMWH) produces less bone loss and
osteoporosis than unfractionated heparin [60]. Both heparin
and LMWH decrease osteoblast function; however, heparin
i n c reases osteoclast number and activity and LMWH does
not [59,60]. Heparin is sequestered in bone for an extended
period, and its effects on bone loss are not immediately
reversible when heparin therapy is stopped [59].
T hy r oid Hormone
Many patients can become hypothyroid after HCT-con-
ditioning regimens [37,61-64] and require thyroid hormone
replacement. Thyroid hormone replacement closely moni-
tored by a physician has not been associated with clinically
evident bone loss; however, elevated levels of thyroid hor-
mone (and thyroid hormone overreplacement) are associ-
ated with osteoporosis [65]. Thyroid hormone incre a s e s
bone remodeling and directly stimulates osteoblast produc-
tion of bone matrix proteins; however, it also incre a s e s
osteoclast number, the number of resorption sites, and the
ratio of resorptive to formative surfaces. The net result of
elevated thyroid hormone levels is that osteoclast activity
predominates, with a resultant loss of bone mass [66].
G r a n ulocyte Colon y - S t i m ulating F a c t o r
G-CSF administration decreases bone mineral density
in humans [15,67,68]. G-CSF is secreted by osteoblasts and
stimulates osteoclastogenesis in vivo and in vitro but at a
much lower rate compared with M-CSF and GM-CSF
Figure 4. Drugs on bone function. Bone remodeling can be affected by sys-
temic hormones and transplant-related therapies. Cyclosporine, glucocorticoids,
and estrogen deficiency decrease bone matrix formation. Glucocorticoids, tumor-
derived parathyroid hormone–related protein, and estrogen deficiency increase
osteoclast formation and activity through induction of osteoblast-derived
cytokines. Osteoclast resorption and bone losses can be inhibited by bisphospho-
nates, estrogen, and calcitonin therapy [10].
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[69]. G-CSF administration not only mobilizes granulo-
cytes but  also increases osteoclast  numbers. G-CSF
hematopoietic cell mobilization and G-CSF support after
high-dose chemotherapy are often part of the standard
HCT regimen. Short - t e rm G-CSF induces osteoclastic
bone resorption [68] and may be a factor in the pathogene-
sis of osteoporosis following HCT.
K i d n e y Dysfunction
Hematopoietic cell transplantation and its related thera-
pies (cyclosporine, amphotericin, furosemide, and other
d i u retics) can result in renal dysfunction. This dysfunction
could lead to decreased 1,25(OH)2VitD3 production and
magnesium and calcium wasting, which would result in ele-
vated levels of PTH and resultant osteoclastic bone resorp-
tion, possible bone formation problems, and overall bone
losses. Renal bone disease (renal osteodystrophy) can be
caused by acidosis, hyperphosphatemia, low seru m
1,25(OH)2VitD3, and secondary hyperparathyroidism [70].
M a l a b s o r p t i o n
G a s t rointestinal losses of calcium and magnesium
resulting from graft-versus-host disease, chemotherapy and
radiation therapy, and infectious and antibiotic-associated
d i a rrhea could play a role in transplantation-related osteo-
p o rosis by stimulating PTH secretion in response to low
serum calcium and vitamin D [23] (Figure 3).
Osteoclast Engraftment and Stem Cell Reinfusion
High-dose chemotherapy with stem cell rescue has been
associated with an increase in markers of bone re s o r p t i o n
and a decrease in markers of bone formation [3]. Increase in
cytokines, G-CSF, and TNF secretion could cause osteo-
clastic activation [71], and damage of resident osteoblasts by
myeloablative therapies may contribute to diminished
osteoblast function [52,53].
Tu m o r -Mediated Osteopor o s i s
Myeloma, certain types of lymphoma, and breast cancer
have a propensity for spread and growth in the bone
t h rough the formation of osteolytic bone lesions. Many of
these tumors produce osteoclast-activating factors, which
enlist normal host osteoclasts to resorb bone [72]. Once the
calcified and organic bone matrix is destroyed, the tumor
cells can expand in its place. Many of these patients have
had marked overall bone losses induced by their disease
prior to stem cell transplantation and consequently are at
high risk for clinically significant bone loss with the prepar-
ative regimen and after HCT regimens. The osteoclast-acti-
vating factors produced by myeloma, breast cancer, and
some lymphomas include PTHrp, IL-6, RANKL, IL-1, and
other uncharacterized factors [9].
THERAPIES FOR TRANSPLANTATION-RELATED
OSTEOPOROSIS
Diagnosing hypogonadism (low estrogen or testos-
t e rone) after hematopoietic cell transplantation and insti-
t u ting hormone replacement where feasible is the most
i m p o rtant intervention to prevent bone loss. There are
cases, however, where hormone replacement is not indicated
and the extent of bone loss is so great that other interven-
tions are necessary. Calcium, vitamin D repletion, and bis-
phosphonate therapy are mainstays of treatment. For exam-
ple, the most effective therapy for glucocort i c o i d - i n d u c e d
bone loss is the early administration of bisphosphonates
[41]. Bisphosphonate suppression of bone resorption has
been known for more than 30 years. Bisphosphonates are
analogues of pyrophosphate, and modifications of the 2 lat-
eral chains on the carbon atom affect the potency of the
compound [73]. Bisphosphonates bind to the bone mineral
and are then taken up by osteoclasts during their initiation of
resorption. In vitro and in vivo studies also show that bisphos-
phonates inhibit osteoclast activity, induce osteoclast apo-
ptosis, and decrease osteoclast re c ruitment by acting on
osteoblasts [74]. The exact molecular mechanism is incom-
pletely understood. Fisher et al. have recently shown that
n i t rogen-containing bisphosphonates like alendronate and
p a m i d ronate act directly on osteoclasts to inhibit the rate-
limiting step in the cholesterol biosynthesis pathway essential
for osteoclast function [75]. Inside the osteoclast, alen-
d ronate interf e res with the generation of geranylgeranyl-
diphosphate by inhibition of an enzyme in the cholestero l
biosynthesis pathway, resulting most likely in a loss of
p renylation of GTP-binding proteins that control cyto-
skeletal function, vesicular trafficking, and apoptosis. Many
bisphosphonates are currently available that differ in their
potency to inhibit osteoclastic resorption. For example,
pamidronate is 100 times more potent than etidronate, and
alendronate is 1000 times more potent than etidronate.
Other treatment and preventive therapies for osteope-
n i a / o s t e o p o rosis include: (1) use of the lowest dose of glu-
c o c o rticoid with the shortest half life, (2) weight-bearing
e x e rcise, (3) calcium intake of at least 1500 mg per day, and
(4) maintenance of serum 1,25(OH)2VitD3 at upper limits
of normal levels. Mundy et al. have recently demonstrated
that the statins (drugs that inhibit 3-hydro x y - 3 - m e t h y l g l u-
t a ryl coenzyme A [HMG CoA] reductase) increase bone
f o rmation in rodents by increasing expression of BMP2
[76]. Statins such as Lovostatin are frequently used to
lower cholesterol, and their role in preventing osteoporo s i s
and increasing bone mineral density is currently under
i n v e s t i g a t i o n .
CONCLUSION
Hematopoietic cell transplantation and its related thera-
pies can result in clinically significant bone loss. Induction
of hypogonadism, alteration of serum calcium levels, induc-
tion of PTH, and direct toxic effects on the bone remodel-
ing unit (osteoclasts and osteoblasts) result in net bone
resorption and loss of bone mass. Early recognition of this
p roblem and early intervention can decrease the negative
impact of these therapies on bone mineral density, fracture
risk, and overall quality of life.
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